<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04553510</url>
  </required_header>
  <id_info>
    <org_study_id>20160101</org_study_id>
    <secondary_id>SYS-2016004</secondary_id>
    <nct_id>NCT04553510</nct_id>
  </id_info>
  <brief_title>Treatment of Bevacizumab Followed by Steroid in RN</brief_title>
  <official_title>Treatment of Bevacizumab Followed by Steroid in Radiation-induceded Brain Injury：a Randomized，Controlled and Single-blind Clinical Trail</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treatment of bevacizumab followed by steroid may have a better effect on patients with&#xD;
      radiation-induced brain injury.This randomized trial aims to investigate whether treatment of&#xD;
      bevacizumab followed by steroid may alleviate radiation-induced brain injury in patients with&#xD;
      nasopharyngeal carcinoma. The effect will be compared with outcomes in patients receiving&#xD;
      steroid therapy&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Radiation-induced brain injury is a severe complication of radiotherapy in patients with&#xD;
      Nasopharyngeal carcinoma. Current neuroprotective therapies show limited benefit in&#xD;
      ameliorating this complication of radiotherapy. This study is a randomized, single blind&#xD;
      clinical study. The primary aim of this study is to determine whether treatment of&#xD;
      bevacizumab followed by steroid can alleviate radiation-induced brain injury in patients with&#xD;
      nasopharyngeal carcinoma, and to compare the treating effect between combination of&#xD;
      bevacizumab and steroid and bevacizumab alone.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2016</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in magnetic resonance imaging (MRI) of radiation-induced brain necrosis in patients</measure>
    <time_frame>Change form baseline to evaluation at 12 weeks</time_frame>
    <description>Change in MRI of radiation-induced brain necrosis in patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of neurologic function of patients after treatment</measure>
    <time_frame>Change from baseline to evaluation at 12 weks.</time_frame>
    <description>Change of neurologic function assessed using LENT/SOMA sacle of patients after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of quality of life of patients after treatment</measure>
    <time_frame>Change from baseline to evaluation at 12 weeks.</time_frame>
    <description>Change of quality of life using QOL scale of patients after treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">86</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <condition>Adverse Effect of Radiation Therapy</condition>
  <condition>Brain Injuries</condition>
  <arm_group>
    <arm_group_label>Bevacizumab and steroid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bevacizumab 5mg / kg, once every two weeks, a total of 6 weeks of 4 courses, sequential prednisone 10mg / d orally, the total course of 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bevacizumab and placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bevacizumab 5mg / kg, once every two weeks, a total of 6 weeks of 4 courses, sequential placebo 2 pills per day orally, the total course of 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab and steroid</intervention_name>
    <description>Bevacizumab 5mg / kg, once every two weeks, a total of 6 weeks of 4 courses, sequential prednisone 10mg / d orally, the total course of 12 weeks.</description>
    <arm_group_label>Bevacizumab and steroid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab and placebo</intervention_name>
    <description>Bevacizumab 5mg / kg, once every two weeks, a total of 6 weeks of 4 courses, sequential placebo 2 pills per day orally, the total course of 12 weeks.</description>
    <arm_group_label>Bevacizumab and placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients must have received radiotherapy for histologically confirmed nasopharyngeal&#xD;
             carcinoma.&#xD;
&#xD;
          2. Prior irradiation &gt;/= 6 months prior to study entry.&#xD;
&#xD;
          3. Radiographic evidence to support the diagnosis of radiation-induced brain necrosis&#xD;
             without tumor recurrence.&#xD;
&#xD;
          4. Age&gt;/= 18 years. Because on dosing or adverse event data are currently not available&#xD;
             on the use of bevacizumab in patients &lt;18years old.&#xD;
&#xD;
          5. No prior bevacizumab therapy.&#xD;
&#xD;
          6. No evidence of very high intracranial pressure that suggests brain hernia and needs&#xD;
             surgery.&#xD;
&#xD;
          7. Fertile women who are willing to take contraception during the trial.&#xD;
&#xD;
          8. Routine laboratory studies with bilirubin &lt;/=2 * upper limits of normal (ULN),&#xD;
             aspartate aminotransferase (AST or SGOT) &lt; 2 * ULN, creatinine &lt;1.5 * ULN, red-cell&#xD;
             count &gt;/= 4,000 per cubic millimeter; white-cell count &gt;/=1500 per cubic millimeter,&#xD;
             platelets &gt;/= 75,000 per cubic millimeter; Hb &gt;/=9.0. PT, APTT, INR in a normal range.&#xD;
&#xD;
          9. If with history of seizures, patients should be on anticonvulsant therapy. However,&#xD;
             preference will be enzyme-non-inducing anticonvulsants.&#xD;
&#xD;
         10. Ability to understand and willingness to sign a written informed consent document.&#xD;
&#xD;
         11. The patient has no active bleeding or pathological condition that carries a high risk&#xD;
             of bleeding; there is no evidence of serious or non-healing wound, ulcer or bone&#xD;
             fracture.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. evidence of metastatic disease;&#xD;
&#xD;
          2. evidence of tumor invasion to major vessels(e.g. the carotid);&#xD;
&#xD;
          3. history of bleeding related to tumor or radiotherapy during or after the completion of&#xD;
             radiation.&#xD;
&#xD;
          4. Evidence of active central nervous system hemorrhage.&#xD;
&#xD;
          5. History of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess&#xD;
             within 28 days prior to study enrollment.&#xD;
&#xD;
          6. inadequately controlled hypertension (systolic blood pressure (SBP) &gt; 140 mmHg and/or&#xD;
             diastolic blood pressure (DBP) &gt; 90 mmHg despite antihypertensive medication)&#xD;
&#xD;
          7. Severe complications: 1) History of large vessel cerebrovascular accident (CVA) within&#xD;
             6 months; 2) Myocardial infarction or unstable angina within 6 months; 3) New York&#xD;
             heart association grade II or greater congestive heart failure; 4) Serious and&#xD;
             inadequately controlled cardiac arrhythmia; 5) Significant vascular disease (e.g.&#xD;
             aortic aneurysm, history of aortic dissection); 6) Clinically significant peripheral&#xD;
             vascular disease; 7) severe infection.&#xD;
&#xD;
          8. Evidence of bleeding diathesis or coagulopathy.&#xD;
&#xD;
          9. Patients who have received steroid therapy for radiation-induced brain necrosis before&#xD;
             the study.&#xD;
&#xD;
         10. History of anaphylactic response to bevacizumab.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tang Yamei, Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>sun yat-sen memorial hospital,sun yat-sen universicy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tang Yamei, Ph.D</last_name>
    <phone>86-13556001992</phone>
    <email>yameitang@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yi Li, Ph.D</last_name>
    <phone>86-15018761512</phone>
    <email>1024254327@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tang Yamei, Ph.D</last_name>
      <phone>86-20-81332619</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>May 5, 2017</study_first_submitted>
  <study_first_submitted_qc>September 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2020</study_first_posted>
  <last_update_submitted>September 14, 2020</last_update_submitted>
  <last_update_submitted_qc>September 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</investigator_affiliation>
    <investigator_full_name>Yamei Tang</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
    <mesh_term>Brain Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

